azd-3199
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00713271)
Timeline
Indications
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545103 ↗
Also known as
- azd3199
- azd3199
- azd-3199
- azd-3199
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01348139 | Phase 2 | May 1, 2011 | AstraZeneca |
| NCT01222442 | Phase 1 | Nov 1, 2010 | AstraZeneca, IQVIA |
| NCT00929708 | Phase 2 | Jun 1, 2009 | AstraZeneca, Medical University of Lodz |
| NCT00772759 | Phase 1 | Oct 1, 2008 | AstraZeneca, Chiltern International |
| NCT00713271 | Phase 1 | Aug 1, 2008 | AstraZeneca, AZ Lund |
| NCT00736489 | Phase 2 | Aug 1, 2008 | AstraZeneca, Lund University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2008 |
| AZ Lund | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Chiltern International | For profit | 1 | 0 | 1 | 2008 |
| IQVIA | For profit | 1 | 0 | 1 | 2010 |
| Lund University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Medical University of Lodz | Academic/Hospital | 1 | 0 | 1 | 2009 |
6 organizations
Page 1 / 1